INTRODUCTION
The role of epigenetic alterations, including the acetylation status of histones and DNA methylation, has been an impor tant focus in studies on the development of human cancers, and such changes are often an early event in tumorigenesis [1, 2] . Histone deacetylase (HDAC) family members remove acetyl groups from the lysine residues of histones, increasing ionic interactions between histones and DNA, and resulting in the formation of an inactive chromatin structure that re presses DNA transcription [3] . Therefore, increased deacetyl ation of histones leads to cell proliferation, apoptosis, cell mi gration, and invasion via inactivation of tumor suppressor genes [4] . Recent studies using HDAC inhibitors (HDACIs) have demonstrated the in vivo and in vitro activities of HDACs affecting the cell cycle, apoptosis, and the differentiation of various cancers [5] , and one of these HDACIs, suberoylanilide hydroxamic acid (SAHA), has been approved for the treat ment of cutaneous Tcell lymphoma [6] .
A total of 18 human HDAC isoenzymes have been de scribed to date, and they are categorized into four classes: class I HDACs (HDAC1, HDAC2, HDAC3, and HDAC8) are relat ed to the yeast RPD3 deacetylase; class II HDACs are catego Purpose: DNA deacetylation by histone deacetylase (HDAC) is an important mechanism involved in the oncogenic tumorigene sis of breast cancer. Previous studies have reported an associa tion of the estrogen receptor (ER) with HDACs and demonstrat ed the efficacy of HDAC inhibitors for the treatment of breast cancers via in vitro experiments. In this study, we examined the association of HDAC expression with clinicopathological para meters and diseasespecific survival. Methods: Immunohisto chemical (IHC) analysis of HDAC1, HDAC2, HDAC3, and HDAC6 was performed using tissue microarrays in 300 invasive ductal carcinomas. IHC scoring was determined by multiplication of the intensity (0 to 3) and the proportion (0 to 4) of staining, and we classified tumors into low and highHDAC expression groups. Results: High expression of HDAC1 was correlated with the mo lecular subtype (p= 0.001) and human epidermal growth factor 2 (HER2) amplification (p= 0.012). High expression of HDAC6 was correlated with a younger age (p< 0.001), ER expression (p= 0.025), progesterone receptor expression (p= 0.034), molecular subtype (p= 0.023), and HER2 amplification (p= 0.011). High HDAC1 expression was correlated with luminal A tumors (p= 0.001), while high HDAC6 expression was more common in lu minal B tumors (p= 0.023). Although the expression of HDACs did not exhibit prognostic significance in the entire cohort, high expression of HDAC1 and HDAC6 was associated with im proved overall survival (OS) in patients with ERpositive tumors (p= 0.017 and p= 0.029, respectively), and high expression of HDAC2 was correlated with improved OS in ERnegative tumors (p= 0.048) on univariate analysis. Furthermore, high HDAC6 ex pression was associated with improved diseasefree survival (p= 0.048) on multivariate analysis. Conclusion: HDAC1 expression is significantly correlated with the molecular subtypes of tumors, with the highest expression being observed in luminal A tumors. HDAC6 is a significantly correlated with ER expression and the molecular subtype, thereby supporting the estrogen regulatory property of HDAC6. HDAC1 and HDAC6 expression are good prognostic factors for ERpositive tumors.
rized into class IIa (HDAC4, HDAC5, HDAC7, and HDAC9) and class IIb (HDAC6 and HDAC10) and are homologous to the yeast Hda1 deacetylase; and class III HDACs include seven HDACs (SIRT1 to SIRT7), which show homology with the yeast Sir2 family [7] . Among these categories, class I and II HDACs are expressed at high levels in some cancers and ap pear to be involved in their carcinogenesis [2, 8] .
In breast cancers, HDACs have been highlighted due to sev eral in vivo and in vitro studies demonstrating the increased ac tivity of HDACs and the antitumor activity of HDACIs [9] . The most well known mechanism of action of HDACs involves their interaction with hormonal receptors (HR). Recent studies have revealed that the transcription of estrogen receptors (ERs) is regulated by epigenetic modifications, and they have de scribed the efficacy of HDACIs through the reexpression of ERs [1] . Furthermore, the efficacy of HDACIs in treating hu man epidermal growth factor 2 (HER2)amplified breast can cers has been reported in several in vitro studies [10, 11] .
Several studies have focused on class I HDACs, especially HDAC1, HDAC2, and HDAC3, and an ERdependent class IIb HDAC, HDAC6, investigating their roles in breast carci nogenesis as well as their prognostic significances [2, 9, 12, 13] . In this study, we analyzed the expression of HDAC1, HDAC2, HDAC3, and HDAC6 through immunohistochemical (IHC) analysis using a tissue microarray. We also analyzed the corre lation with clinicopathological parameters and the prognostic significance of HDACs.
METHODS

Patient data and histopathological features
A total of 300 histologically proven invasive ductal carcino ma patients who underwent curative surgery between January 2003 and December 2008 at Hallym Sacred Heart Hospital were included in this study. Patients exhibiting pT4 disease or stage IV disease and those lacking pathology results were ex cluded from the study. Clinicopathological parameters, includ ing tumor size, nodal status, margin status, and HER2 status were retrieved from pathology reports. HER2 status was inter preted according to the American Society of Clinical Oncolo gy/College of American Pathologists guideline recommenda tions [14] . Other pathological parameters, including the histo logic grade (HG), lymphatic tumor invasion, Ki67 labeling index, and HR status, were evaluated after reviewing whole slides. HR statuses were evaluated according to the Allred score (Harvey) and a tumor was interpreted positive when the total score was > 2. Breast cancer molecular subtypes were classified according to IHC profiles as described previously by Cheang et al. [15] . We obtained survival data from the breast cancer database of our institution and the Korean National Cancer Center database. This study was approved by the Insti tutional Ethics Committee of Hallym Sacred Heart Hospital (2014I043).
IHC staining
IHC staining was performed on paraffinembedded tissue sections using an automated IHC stainer (Ventana BenchMark TX; Ventana Medical System Inc., Tucson, USA) and iVIEW diaminobenzidine detection kits (Ventana Medical System Inc.), as previously described [16] . The following antibodies were used: monoclonal mouse antiHDAC1 (dilution, 1:4,000; Abnova, Taipei, Taiwan); polyclonal rabbit antiHDAC2 (dilu tion, 1:2,000; Abnova); polyclonal rabbit antiHDAC3 (dilution, 1:100; Proteintech, Chicago, USA); monoclonal rabbit anti HDAC6 (dilution, 1:200; Cell Signaling Technology, Beverly, USA); and monoclonal mouse p53 (dilution, 1:500; Novocastra, New Castle, UK). Briefly, IHC staining was performed as fol lows: 4μm thick tissue sections were deparaffinized using EZ Prep solution (Ventana Medical System Inc.). A CC1 standard (pH 8.4 buffer containing Tris/borate/ethylenediaminetetra acetic acid) was applied for antigen retrieval at 99°C for 60 min utes. The iVIEW inhibitor was blocked at 37°C for 4 minutes. The slides were incubated with the primary antibodies at 42°C for 32 minutes, followed by a secondary antibody against iVEW biotinylated Ig at 37°C for 8 minutes. The slides were subse quently incubated in iVIEW streptavidin HRP at 37°C for 8 minutes, followed by diaminobenzidine plus the H2O2 substrate for 8 minutes and then counterstained with hematoxylin and bluing reagent at 37°C. The reaction buffer (pH 7.6 Tris buffer) was used as the wash solution.
Interpretation of IHC results
The IHC staining associated with HDACs was interpreted based on the intensity (0, negative; 1, mild; 2, moderate; 3, strong) and the proportion of positive cells (0, negative; 1, < 10%; 2, ≥ 10% and < 33%; 3, ≥ 33% and < 66%; 4, ≥ 66%). The HDAC IHC scores were calculated through multiplication of the intensity and the proportion as described previously [2] . We classified the examined cases into two groups according to their IHC scores as follows: low expression (0-6) or high ex pression (8) (9) (10) (11) (12) . The IHC staining of p53 was interpreted as positive when more than 10% of the tumor cells showed nu clear staining for p53.
Statistical analysis
IBM SPSS version 21 (IBM Inc., Armonk, USA) was used for statistical analysis. The chisquare test, Spearman correla tion coefficient, and Fisher exact test were used for correlation analysis. Survival analysis was performed using the Kaplan Meier method and a logrank test for univariate analysis, and the Coxproportional hazard models method for multivariate analysis. pvalues of 0.05 or less were considered statistically significant.
RESULTS
Clinical and pathological characteristics
The clinicopathological characteristics of the 300 cases are summarized in Table 1 . The median age of the patients at the time of diagnosis was 51 years (range, 25-86 years), and the median followup duration was 70 months (range, 1-120 months). Most of the tumors were classified as pT1 (180 cases, 60.0%) or pT2 (114 cases, 38.0%), and the remaining six cases were classified as pT3. Younger patients ( ≤ 50 years) showed a higher incidence of both ER (67.1% vs. 53.5%, p= 0.018) and progesterone receptor (PR) expression (70.6% vs. 51.6%, p= 0.001). HER2 amplification was also observed more frequently in younger patients (32.2% vs. 19.7%, p= 0.017). Tumors with a triplenegative phenotype were more common in older pa tients (28.0% vs. 11.9%, p= 0.001).
IHC expression and correlation of HDACs with clinicopathological parameters
HDAC1 and HDAC2 were expressed in the nuclei of both normal and malignant epithelial cells. HDAC3 was observed in both the cytoplasm and the nuclei, and HDAC6 was observed in the cytoplasm (Figure 1) Table 3 ). There was no significant correla tion between the expression of HDAC2 or HDAC3 and any of the available clinicopathological parameters.
Correlation of HDACs with survival
Among the examined clinicopathological parameters, tra ditional prognostic factors including pT status (p = 0.009), nodal status (p < 0.001), molecular subtype (p = 0.048), and the presence of lymphatic invasion (p= 0.025) showed statisti cally significant associations with overall survival (OS) on univariate analysis. Univariate analysis also revealed that pT status (p= 0.021), nodal status (p< 0.001), molecular subtype (p= 0.029), the presence of lymphatic invasion (p= 0.016), ER expression (p = 0.008), and PR expression (p = 0.011) were significantly associated with diseasefree survival (DFS). None of the HDACs showed a significant correlation with either OS (Table 4) . Although the prognostic significances of HDACs were not observed in the entire cohort, prognostic impacts of HDAC1 and HDAC6 expression were observed in certain subgroups of patients; in patients with ERpositive tumors, high HDAC1 expression predicted a significantly improved OS (p= 0.017) (Figure 2A) , and high HDAC6 expression also resulted in improved OS (p= 0.029) ( Figure 2C ) on univariate analysis. However, high HDAC1 expression was not associat ed with improved DFS (p= 0.421), but high HDAC6 expres sion was associated with improved DFS (p = 0.021) ( Figure  2E ). Multivariate analysis in ERpositive tumors revealed that none of the parameters showed a statistically significant asso ciation with OS, but a high HG (p= 0.023) and low HDAC6 expression (p = 0.027) predicted a poor DFS (Table 5) . Fur thermore, high expression of HDAC6 was strongly associated with a better OS and DFS in luminal B tumors (p = 0.001) ( Figure 2D, F) . High expression of HDAC2 was correlated with a significantly improved OS in patients with ERnegative tumors on univariate analysis (p=0.048) ( Figure 2B ), but 
DISCUSSION
We demonstrated differential expression of HDAC1, HDAC2, HDAC3, and HDAC6 via IHC in invasive ductal carcinomas of the breast. The expression of HDAC1 was significantly asso ciated with HER2 amplification, and high expression of HDAC6 was significantly correlated with a younger age, HR status, HER2 amplification, and p53 expression.
The association of HDAC activity with estrogen expression has been investigated in several studies. HDAC1 interacts with ERα in vitro and in vivo and suppresses ERα transcrip tion through interaction with the activation function 2 do main of HDAC1 and the DNAbinding domain of ERα [1] . HDAC6 is also an estrogenregulated protein [13] and is re lated to cell migration and the transport of misfolded proteins via the deacetylation of tubulin [17, 18] . Although the above in vitro studies reported an association of HDAC activities with ER expression, the following IHC studies obtained inconsis tent results. Müller et al. [2] reported an association of class I HDAC expression with HR status. They found a significant correlation between HDAC1positive status and HRpositive status and a significant association of HDAC 2 and HDAC3 with a negative HR status. In contrast, Krusche et al. [9] ob served a significant correlation between increased expression of HDAC3 and HRpositive tumors. We did not observe any significant associations between HR status and the expression of HDAC1, HDAC2, and HDAC3. On the other hand, a posi tive correlation between HDAC6 expression and HR status was observed in our study, and Zhang et al. [12] also reported higher HDAC6 expression in HRpositive cases, although they failed to demonstrate statistical significance. The incon sistent, conflicting results regarding the correlation of HDACs and HR may suggest that other regulatory factors exist be tween these two parameters. Although we did not observe a positive correlation between HDAC1 expression and HR sta tus, we did detect increased expression of HDAC1 in luminal A tumors.
The molecular interactions and associations between HDACs and HER2 have not been well documented in previous reports.
Several studies have shown that HDACIs can significantly en hance trastuzumabinduced growth inhibition and apoptosis in erbB2overexpressing breast cancer cells, suggesting an associ ation between HER2 and HDACs [10, 11, 19] . Müller et al. [2] reported that high HDAC2 expression was significantly corre lated with overexpression of HER2, and in vitro studies have detected an association of HDAC6 and HER2 in oncogenic tu morigenesis [20] . In the present study, high expression of HDAC1 was found to be significantly associated with a nega tive HER2 status, but there was no correlation between high HDAC2 expression and HER2 status. High HDAC6 expression was significantly correlated with HER2 amplification in our study, and the high HDAC6 expression observed in luminal B type tumors can be explained by the positive correlation of HDAC6 with HR and HER2 amplification.
HDACs have been investigated as potential prognostic fac tors for breast cancer, but there are conflicting data regarding their prognostic value. Although Krusche et al. [9] suggested that elevated HDAC1 expression is correlated with improved survival in small and welldifferentiated tumors, in patients with HRpositive tumors, and tumors with a HER2negative phenotype, Müller et al. [2] did not observe any prognostic significance of HDAC1, HDAC2, and HDAC3 expression. El evated expression of HDAC6 was initially reported to be cor related with more aggressive forms of breast cancer, and it was regarded as a poor prognostic factor [21] . However, later stud ies by Zhang et al. [12] and Saji et al. [13] obtained opposite results, and Suzuki et al. [22] found that the expression of HDACs was significantly reduced in association with the pro gression from a normal ductal epithelium, to ductal carcino ma in situ, to invasive ductal carcinoma, suggesting an inverse correlation of HDAC expression with tumor progression in breast cancers. These conflicting results may be associated with adjuvant therapy after surgery. The guidelines for breast cancer patients in Korea recommend the use of anthracyclinebased regimens for patients without nodal metastasis, anthracycline plus taxanebased regimens for patients with lymph node me tastasis, antihormonal therapy for patients with ERpositive tu mors, and trastuzumab for patients with HER2positive tu mors [23] . Taxanes act by shifting the dynamic equilibrium between tubulin and microtubules to the direction of microtu bule assembly; HDAC6 is a regulator of tubulin, which is the target of taxanes [17] . Furthermore, ERα directly regulates tumor sensitivity to taxanes, primarily by estrogeninduced deacetylation of tubulin [24] , and combination therapy with taxanes plus antihormonal therapy may affect HDAC func tion, resulting in better therapeutic responses in HDACposi tive/ERpositive tumors. Furthermore, the prognostic signifi cance of HDAC6 was highlighted in luminal B tumors (HR positive, and HER2 positive or high Ki67 indices). HER2 in hibits the metastasis suppressor RECK via Sp1 and HDAC1 dependent mechanisms [25] and is also regulated by HDAC6 via hsp60 deacetylation [19] . Therefore, the therapeutic re sponse to antihormonal therapy and trastuzumab may influ ence the OS and DFS of patients with ERpositive tumors and luminal B tumors in the present study.
HDACIs are one of the new agents for the treatment of vari ous human cancers, and they showed therapeutic effects through the inhibition of HDAC activity in breast cancer [11, 26, 27] . One such HDACI, SAHA, results in the acetylation of various proteins, and it was shown to induce hsp90 acetyla tion, leading to polyubiquitylation and the accumulation of misfolded client proteins, including HER2, AKT, cRaf, Bcr Abl, and mutant FLT3 [19] . Furthermore, HDACIs inhibit the chaperone function of hsp90, resulting in the proteasomal degradation of AKT and cRaf, two of the most prominent progrowth and prosurvival proteins in cancer cells [28] . In ad dition, HDACIs suppress ERα expression, but promote ERβ expression, resulting in anticancer activity toward breast can cer [29] , and Munster et al. [30] reported an improved re sponse to a combination of vorinostat and hormone therapy in metastatic breast cancers.
Our study has several limitations; this cohort was composed of a limited number of patients with different followup dura tions, most of the tumors in our study were of a less advanced stage, and only a small number of patients showed recurrence or death from their cancers. Although we have observed the prognostic significances of HDACs in some subgroups, the analyzed populations of these groups were small for multivari ate analysis. Therefore, multivariate analysis was not performed for luminal B tumors, and a few traditional prognostic factors, including pT stage and nodal status, did not correlate with sur vival in ERpositive tumors. In addition, although the expres sion levels of HDACs were well correlated with each other, each HDAC subtype showed different associations with the clinical parameters and had different prognostic values. There fore, an additional study is needed with a larger number of pa tients and with longer followup durations. Additionally, the association of HDACs with therapeutic effects, including anti hormonal therapy and HER2targeted therapy, should be clari fied in a large standardized patient group in the future.
In summary, we identified a correlation between HDACs and HR and HER2 in breast cancer via IHC analysis. Elevated expression of HDAC6 was significantly correlated with HER2 amplification and HR expression, and HDAC1 expression was higher in tumors without HER2 amplification. Tumors exhibiting high HDAC1 expression were closely associated with the luminal A phenotype, and luminal B tumors ex pressed HDAC6 more frequently compared with other types of tumors. HDAC1 and HDAC6 expression were positively correlated with a prolonged OS in ERpositive tumors, and the prognostic significance of HDAC6 was highlighted in tu mors with a luminal B subtype. Elevated expression of HDAC2 resulted in good OS in ERnegative tumors.
The positive correlation of HDAC1 and HDAC6 expression with prolonged OS was highlighted in ERpositive tumors of the breast. These findings suggest an association of HDAC act ivity with other clinical factors and indicate its prognostic val ue in HRpositive breast cancers.
